These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 24327015)

  • 1. An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.
    Linton A; Cheng YY; Griggs K; Schedlich L; Kirschner MB; Gattani S; Srikaran S; Chuan-Hao Kao S; McCaughan BC; Klebe S; van Zandwijk N; Reid G
    Br J Cancer; 2014 Jan; 110(2):510-9. PubMed ID: 24327015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma.
    Kato T; Lee D; Wu L; Patel P; Young AJ; Wada H; Hu HP; Ujiie H; Kaji M; Kano S; Matsuge S; Domen H; Kanno H; Hatanaka Y; Hatanaka KC; Kaga K; Matsui Y; Matsuno Y; De Perrot M; Yasufuku K
    Int J Oncol; 2016 Dec; 49(6):2411-2420. PubMed ID: 27840913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
    Zanellato I; Colangelo D; Osella D
    Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
    Maille E; Brosseau S; Hanoux V; Creveuil C; Danel C; Bergot E; Scherpereel A; Mazières J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Langlais A; Morin F; Levallet G; Zalcman G
    Br J Cancer; 2019 Feb; 120(4):387-397. PubMed ID: 30739911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
    Urso L; Cavallari I; Silic-Benussi M; Biasini L; Zago G; Calabrese F; Conte PF; Ciminale V; Pasello G
    Oncotarget; 2017 Jul; 8(27):44232-44241. PubMed ID: 28562336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
    Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
    Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
    [No Abstract]   [Full Text] [Related]  

  • 8. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy.
    Hegedüs L; Okumus Ö; Mairinger F; Ploenes T; Reuter S; Schuler M; Welt A; Vega-Rubin-de-Celis S; Theegarten D; Bankfalvi A; Aigner C; Hegedüs B
    Lung Cancer; 2023 Apr; 178():237-246. PubMed ID: 36907051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
    Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
    Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
    Williams M; Kirschner MB; Cheng YY; Hanh J; Weiss J; Mugridge N; Wright CM; Linton A; Kao SC; Edelman JJ; Vallely MP; McCaughan BC; Cooper W; Klebe S; Lin RC; Brahmbhatt H; MacDiarmid J; van Zandwijk N; Reid G
    Oncotarget; 2015 Sep; 6(27):23480-95. PubMed ID: 26125439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
    Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
    Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-occurring Mutations of Tumor Suppressor Genes,
    Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
    [No Abstract]   [Full Text] [Related]  

  • 14. Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma.
    Mogi A; Koga K; Aoki M; Hamasaki M; Uesugi N; Iwasaki A; Shirakusa T; Tamura K; Nabeshima K
    Virchows Arch; 2013 Jan; 462(1):83-93. PubMed ID: 23187830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
    J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
    Edakuni N; Ikuta K; Yano S; Nakataki E; Muguruma H; Uehara H; Tani M; Yokota J; Aizawa H; Sone S
    Oncol Res; 2006; 16(5):235-43. PubMed ID: 17294804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
    Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E
    BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma.
    Kato T; Lee D; Wu L; Patel P; Young AJ; Wada H; Hu HP; Ujiie H; Kaji M; Kano S; Matsuge S; Domen H; Kaga K; Matsui Y; Kanno H; Hatanaka Y; Hatanaka KC; Matsuno Y; de Perrot M; Yasufuku K
    Int J Oncol; 2016 Aug; 49(2):448-56. PubMed ID: 27279560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
    Suraokar MB; Nunez MI; Diao L; Chow CW; Kim D; Behrens C; Lin H; Lee S; Raso G; Moran C; Rice D; Mehran R; Lee JJ; Pass HI; Wang J; Momin AA; James BP; Corvalan A; Coombes K; Tsao A; Wistuba II
    Ann Oncol; 2014 Jun; 25(6):1184-92. PubMed ID: 24669013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.